GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative Study

BACKGROUND: Pre-clinical data have suggested a therapeutic role of Hedgehog (Hh) pathway inhibitors in chondrosarcoma. METHODS: This phase II trial included patients with progressive advanced chondrosarcoma. They received GDC-0449 150 mg/day (days 1–28, 28-day cycle). The primary end point was the 6...

Full description

Saved in:
Bibliographic Details
Main Authors: Italiano, A., Le Cesne, A., Bellera, C., Piperno-Neumann, S., Duffaud, F., Penel, N., Cassier, P., Domont, J., Takebe, N., Kind, M., Coindre, J.-M., Blay, J.-Y., Bui, B.
Format: Artigo
Language:Inglês
Published: Oxford University Press 2013
Subjects:
Original Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3811907/
https://ncbi.nlm.nih.gov/pubmed/24170610
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdt391
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items